Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial. [electronic resource]
Producer: 20190308Description: 270-279.e3 p. digitalISSN:- 1938-0690
- Adult
- Age Factors
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Docetaxel -- administration & dosage
- Double-Blind Method
- Female
- Humans
- Kaplan-Meier Estimate
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Salvage Therapy -- methods
- Vascular Endothelial Growth Factor Receptor-2 -- antagonists & inhibitors
- Young Adult
- Ramucirumab
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.